Lisa Rojkjaer
Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Lisa Rojkjaer
Rigel Pharmaceuticals Inc reported in an 8-K filed July 1, 2026 that Lisa Rojkjaer resigned as Executive Vice President and Chief Medical Officer, effective June 25, 2026. Lisa Rojkjaer has spoken on 2 earnings calls across 1 company, most recently for Rigel Pharmaceuticals Inc on May 5, 2026.
“Effective June 25, 2026, Lisa Rojkjaer, M.D. ceased serving as Executive Vice President and Chief Medical Officer of the Company and separated from the Company.”
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Rigel Pharmaceuticals Inc (RIGL)
Proxy statement
Start not stated–2026-06-25
Company network
Recorded roles and call appearances connecting this person to public companies.
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2023 | Rigel Pharmaceuticals Inc (RIGL) | Executive Vice President and Chief Medical Officer | — | — |
| 2022 | Rigel Pharmaceuticals Inc (RIGL) | Executive Vice President and Chief Medical Officer | — | — |
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.